Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

MPIP Announces Publication Of Its Latest Recommendations On Improving Transparency In Clinical Trial Data Disclosures In The Online Issue Of The BMJ
  • USA - English


News provided by

Medical Publishing Insights & Practices (MPIP)

Oct 05, 2016, 08:00 ET

Share this article

Share toX

Share this article

Share toX

Beachwood, OH: (PRWEB) October 05, 2016 -- Medical Publishing Insights & Practices (MPIP) today announced the publication of its latest recommendations on improving transparency in clinical trial data disclosures in the online issue of The BMJ (doi: 10.1136/bmj.i5078).

Recommendations to Improve Adverse Event Reporting in Clinical Trial Publications: a Joint Pharmaceutical Industry/Journal Editor Perspective is the latest publication from the MPIP collaboration with leading medical journal editors and industry experts. It calls on clinical trial sponsors, authors, and editors to place greater focus on clinically relevant and informative adverse event (AE) reporting, including highlighting AEs of most relevance to practitioners and their patients, avoiding broad summary statements such as “generally safe” or “well-tolerated,” and presenting more detailed AE data (where appropriate) to offer additional clinically important insight.

These recommendations complement the earlier recommendations in the Consolidated Standards of Reporting Trials (CONSORT) Harms Extension, addressing a critical gap identified by editors and authors for more specific guidance regarding clinically meaningful, informative, and transparent reporting of AEs critical for practical application in the clinical setting.

The publication’s main recommendations for AE reporting from clinical trials include

Recommendation 1 – Identify and communicate the most clinically relevant drug adverse event data as part of a comprehensive safety profile
• Although “clinical relevance” varies from one disease setting to another, it generally includes AEs that affect treatment tolerability and adherence, require upfront monitoring or early intervention, or have serious and long-lasting consequences

Recommendation 2 – Report timing, frequency, duration, and other potentially relevant descriptors when clinically appropriate
• Include such descriptors (for example, the severity of an AE and whether it led to treatment discontinuation) whenever feasible, as these could be more informative and clinically useful than incidence rates alone

Recommendation 3 – Use statistical analysis for clinically relevant adverse events (where appropriate)
• AE reporting should include numerators and denominators for all events; formal statistical analyses should be used selectively, and post hoc analyses should be clearly identified

Recommendation 4 – Avoid use of overly general text descriptions for adverse events, including in abstracts
• Use of overly general terminology is not informative and raises questions about credibility and transparency of publications. Summary statements should be supported with specific and informative data, which is interpreted in the context of the trial design and its limitations

Recommendation 5 – Discuss adverse events findings in the broader context of available evidence and maintain consistency of data across different public reports
• Look beyond the individual publication at hand and understand how the individual trial results relate to the larger body of clinical evidence. Also, multiple reports from the same study should be presented consistently

"A clear understanding of both the beneficial and adverse effects of medical interventions is critical to clinical decision-making. Unfortunately, the reporting of adverse events in clinical trial reports often falls short of the type of information clinicians and patients need. The MPIP recommendations on adverse event reporting in clinical trials provide practical guidance to supplement existing reporting recommendations. Following this guidance promises to substantially improve the usefulness of clinical trial reports,” says Christine Laine, MD, MPH, Editor in Chief, Annals of Internal Medicine.

Although developed for industry-sponsored trials, the adoption of these recommendations would enhance AE reporting in clinical research publications regardless of the funding source and would facilitate better clinical decision-making.

Communicating drug AEs in a more transparent and clinically meaningful manner was one of ten key recommendations to improve the credibility of industry-sponsored publications. Industry experts, members of Medical Publishing Insights & Practices (MPIP), and journal editors from several journals came together in 2014 to discuss ways to improve the communication of AE data. This roundtable included editors from American Journal of Hospice and Palliative Medicine, Annals of Internal Medicine, Canadian Medical Association Journal, Gastroenterology, Gastrointestinal Cancer Research, International Journal of Clinical Practice, Journal of the American Medical Association, Neurology, and The New England Journal of Medicine, as well as industry experts and MPIP members from Amgen, Astellas, AstraZeneca, Biogen, Bristol-Myers Squibb, GlaxoSmithKline, ISMPP, Janssen Research & Development LLC, Johnson & Johnson, Merck, Pfizer, and Takeda.

About MPIP: Medical Publishing Insights & Practices (MPIP) was founded by members of the pharmaceutical industry and the International Society for Medical Publication Professionals (ISMPP) to elevate trust, transparency, and integrity in publishing industry-sponsored research. Current corporate co-sponsors include Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Research & Development LLC, Merck, Pfizer, and Takeda.

You may also access these links for additional information:
• MPIP Website
• MPIP LinkedIn page
• MPIP Twitter page

1. Ioannidis J, et al. Better reporting of harms in randomized trials: an extension of the CONSORT statement. Ann Intern Med. 2004;141(10):781-788. doi: 10.7326/0003-4819-141-10-200411160-00009.
2. Mansi BA, Clark J, David FS, et al. Ten recommendations for closing the credibility gap in reporting industry-sponsored clinical research: a joint journal and pharmaceutical industry perspective. Mayo Clinic Proc. 2012 87(5);424-429. doi: 10.1016/j.mayocp.2012.02.009.

Greg Connel on behalf of, Medical Publishing Insights & Practices (MPIP), +1 (216) 378-8908, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.